The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely on viral vectors.

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...